홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Trifluoroacetic acid → Dipropan-2-yl [3-({4-[({2-[methyl (methylsulfonyl)amino]pyridin-3-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzyl]phosphonate trifluoroacetate

HRID 1947825
인쇄

반응식

HRID 1947825 반응식
[CH3:1][CH:2]([O:4][P:5]([CH2:11][C:12]1[CH:17]=[CH:16][CH:15]=[C:14]([N+:18]([O-])=O)[CH:13]=1)(=[O:10])[O:6][CH:7]([CH3:9])[CH3:8])[CH3:3].Cl[C:22]1[N:27]=[C:26]([NH:28][CH2:29][C:30]2[C:31]([N:36]([CH3:41])[S:37]([CH3:40])(=[O:39])=[O:38])=[N:32][CH:33]=[CH:34][CH:35]=2)[C:25]([C:42]([F:45])([F:44])[F:43])=[CH:24][N:23]=1.[C:46]([OH:52])([C:48]([F:51])([F:50])[F:49])=[O:47]>CO.[Pd]>[F:49][C:48]([F:51])([F:50])[C:46]([OH:52])=[O:47].[CH3:1][CH:2]([O:4][P:5]([CH2:11][C:12]1[CH:17]=[CH:16][CH:15]=[C:14]([NH:18][C:22]2[N:27]=[C:26]([NH:28][CH2:29][C:30]3[C:31]([N:36]([CH3:41])[S:37]([CH3:40])(=[O:39])=[O:38])=[N:32][CH:33]=[CH:34][CH:35]=3)[C:25]([C:42]([F:43])([F:45])[F:44])=[CH:24][N:23]=2)[CH:13]=1)(=[O:10])[O:6][CH:7]([CH3:9])[CH3:8])[CH3:3]
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

6

반응물 3

HCID 6422Trifluoroacetic acidHCID 15205360Dipropan-2-yl(3-nitrobenzyl)phosphonateHCID 57584561N-(3-((2-chloro-5-(trifluoromethyl)pyrimidin-4-ylamino)methyl)pyridin-2-yl)-N-methylmethanesulfonamide

생성물 1

HCID 86654005Dipropan-2-yl [3-({4-[({2-[methyl (methylsulfonyl)amino]pyridin-3-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzyl]phosphonate trifluoroacetate수율 34%

시약·촉매·용매

2
HCID 23938Palladium촉매HCID 887Methanol용매

실험 절차

A mixture of triisopropyl phosphite (500 mg, 2.31 mmol) and 1-bromomethyl-3-nitrobenzene (506 mg, 2.43 mmol) was heated at 100° C. under nitrogen for 3 h. The crude dipropan-2-yl(3-nitrobenzyl)phosphonate thus formed was dissolved in MeOH (5 mL) and hydrogenated in the presence of 5% Pd/C (49 mg) for 2 h. The mixture was filtered and concentrated in vacuo and the dipropan-2-yl(3-aminobenzyl)phosphonate residue heated in a microwave reactor at 105° C. under nitrogen for 40 minutes with N-[3-({[2-chloro-5-(trifluoromethyl)pyrimidin-4-yl]amino}methyl)pyridin-2-yl]-N-methylmethanesulfonamide XLIa (20 mg, 0.051 mmol), TFA (12 uL, 0.15 mmol) and 0.5 mL TFE. The mixture was evaporated to dryness and purified by preparative HPLC to afford 11 mg of dipropan-2-yl[3-({4-[({2-[methyl(methylsulfonyl)amino]pyridin-3-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzyl]phosphonate trifluoroacetate (Example 35, yield: 34%). 1H NMR (400 MHz, CD3OD) δ=1.19 (d, J=6.1 Hz, 6H), 1.28 (d, J=6.1 Hz, 6H), 3.06-3.12 (m, 4H), 3.12-3.19 (m, 4H), 4.51-4.63 (m, 2H), 4.96 (s, 2H), 7.14 (d, J=7.3 Hz, 1H), 7.21-7.28 (m, 1H), 7.29-7.33 (m, 1H), 7.35-7.43 (m, 2H), 7.76 (d, J=7.6 Hz, 1H), 8.21 (s, 1H), 8.45 (dd, J=4.8, 1.8 Hz, 1H). MS (ES+): m/z 631.27 (100) [MH+]; HPLC: tR=1.03 min (UPLC, purity).

후처리

  1. filtrationThe mixture was filtered
  2. concentrationconcentrated in vacuo
  3. customThe mixture was evaporated to dryness
  4. custompurified by preparative HPLC

출처 및 근거

ORD 기록
ord-2134e76469654703aa9b652a5e422659
출처 데이터셋
uspto-grants-2013_03
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08399433B2

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트